Objective Quantitation of EGFR Protein Levels using Quantitative Dot Blot Method for the Prognosis of Gastric Cancer Patients

다국어 초록 (Multilingual Abstract)

Purpose: An underlying factor for the failure of several clinical trials of anti-epidermal growth factor receptor (EGFR) therapies is the lack of an effective method to identify patients who overexpress EGFR protein. The quantitative dot blot method (QDB) was used to measure EGFR protein levels objectively, absolutely, and quantitatively. Its feasibility was evaluated for the prognosis of overall survival (OS) of patients with gastric cancer.
Materials and Methods: Slices of 2×5 μm from formalin-fixed paraffin-embedded gastric cancer specimens were used to extract total tissue lysates for QDB measurement. Absolutely quantitated EGFR protein levels were used for the Kaplan-Meier OS analysis.
Results: EGFR protein levels ranged from 0 to 772.6 pmol/g (n=246) for all gastric cancer patients. A poor correlation was observed between quantitated EGFR levels and immunohistochemistry scores with ρ=0.024 and P=0.717 in Spearman's correlation analysis. EGFR was identified as an independent negative prognostic biomarker for gastric cancer patients only through absolute quantitation, with a hazard ratio of 1.92 (95% confidence interval, 1.05–3.53; P=0.034) in multivariate Cox regression OS analysis. A cutoff of 208 pmol/g was proposed to stratify patients with a 3-year survival probability of 44% for patients with EGFR levels above the cutoff versus 68% for those below the cutoff based on Kaplan-Meier OS analysis (log rank test, P=0.002).
Conclusions: A QDB-based assay was developed for gastric cancer specimens to measure EGFR protein levels absolutely, quantitatively, and objectively. This assay should facilitate clinical trials aimed at evaluation of anti-EGFR therapies retrospectively and prospectively for gastric cancer.

참고문헌 (Reference)

1 Simon RM, "Use of archived specimens in evaluation of prognostic and predictive biomarkers" 101 : 1446-1452, 2009

2 Nakamura Y, "The right treatment of the right patient : integrating genetic profiling into clinical decision making in advanced gastric cancer in Asia" 41 : e166-e173, 2021

3 Yarden Y, "The ERBB network : at last, cancer therapy meets systems biology" 12 : 553-563, 2012

4 Apicella M, "Targeted therapies for gastric cancer : failures and hopes from clinical trials" 8 : 57654-57669, 2017

5 Hembrough T, "Selected reaction monitoring(SRM)analysis of epidermal growth factor receptor(EGFR)in formalin fixed tumor tissue" 9 : 5-, 2012

6 Bonner JA, "Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck" 354 : 567-578, 2006

7 Zhang W, "Quantitative dot blot(QDB)as a universal platform for absolute quantification of tissue biomarkers" 576 : 42-47, 2019

8 Tian G, "Quantitative dot blot analysis(QDB), a versatile high throughput immunoblot method" 8 : 58553-58562, 2017

9 Kim ST, "Prospective feasibility study for using cell-free circulating tumor DNA-guided therapy in refractory metastatic solid cancers : an interim analysis" 1 : 1-15, 2017

10 Fuse N, "Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients" 19 : 183-191, 2016

11 Licitra L, "Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer : analysis of data from the EXTREME and CRYSTAL studies" 49 : 1161-1168, 2013

12 Vermorken JB, "Platinum-based chemotherapy plus cetuximab in head and neck cancer" 359 : 1116-1127, 2008

13 Burtness B, "Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer : an Eastern Cooperative Oncology Group study" 23 : 8646-8654, 2005

14 Han SW, "Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer" 100 : 298-304, 2009

15 Paz-Ares L, "Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer(INSPIRE) : an open-label, randomised, controlled phase 3 study" 16 : 328-337, 2015

16 Thatcher N, "Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer(SQUIRE) : an open-label, randomised, controlled phase 3 trial" 16 : 763-774, 2015

17 Díaz-Serrano A, "Necitumumab for the treatment of advanced non-small-cell lung cancer" 15 : 705-716, 2019

18 Tol J, "Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab" 46 : 1997-2009, 2010

19 Queirós P, "KRAS mutations in microsatellite instable gastric tumours : impact of targeted treatment and intratumoural heterogeneity" 467 : 383-392, 2015

20 Lièvre A, "KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer" 66 : 3992-3995, 2006

21 Hirsch FR, "Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy" 26 : 3351-3357, 2008

22 Hao J, "Improving prognosis of surrogate assay for breast cancer patients by absolute quantitation of Ki67 protein levels using quantitative dot blot(QDB)method" 11 : 737781-, 2021

23 Terashima M, "Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer" 18 : 5992-6000, 2012

24 Stahl P, "Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancer" 15 : 7-, 2015

25 Rüschoff J, "HER2 testing in gastric cancer : a practical approach" 25 : 637-650, 2012

26 Higaki E, "Gene copy number gain of EGFR is a poor prognostic biomarker in gastric cancer : evaluation of 855 patients with bright-field dual in situ hybridization(DISH)method" 19 : 63-73, 2016

27 Park JE, "GC1118, a novel anti-EGFR antibody, has potent KRAS mutation-independent antitumor activity compared with cetuximab in gastric cancer" 22 : 932-940, 2019

28 Nagatsuma AK, "Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma" 18 : 227-238, 2015

29 Sun G, "Expression and characterization analysis of EGFR, PI3K and its phosphorylated protein in different subtypes of breast cancer" 8 : 207-212, 2014

30 Zhang F, "Epidermal growth factor receptor expression and gene copy number analysis in gastric carcinoma samples from Chinese patients" 11 : 173-181, 2016

31 Kim MA, "EGFR in gastric carcinomas : prognostic significance of protein overexpression and high gene copy number" 52 : 738-746, 2008

32 Genova C, "EGFR gene copy number by FISH may predict outcome of necitumumab in squamous lung carcinomas : analysis from the SQUIRE study" 13 : 228-236, 2018

33 Birkman EM, "EGFR gene amplification is relatively common and associates with outcome in intestinal adenocarcinoma of the stomach, gastro-oesophageal junction and distal oesophagus" 16 : 406-, 2016

34 Pirker R, "EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer : analysis of data from the phase 3 FLEX study" 13 : 33-42, 2012

35 Gown AM, "Diagnostic Immunohistochemistry : What can go wrong and how to prevent it" 140 : 893-898, 2016

36 Yu G, "Developing a routine lab test for absolute quantification of HER2 in FFPE breast cancer tissues using quantitative dot blot(QDB)method" 10 : 12502-, 2020

37 Zhang J, "Developing a growing cancer profile database based on quantitative analysis of protein biomarkers in formalin-fixed paraffin-embedded specimens" 16 : 2471-2474, 2020

38 장선희, "Current status and future perspectives of liquid biopsy in non-small cell lung cancer" 대한병리학회 54 (54): 204-212, 2020

39 Li K, "Current molecular targeted therapy in advanced gastric cancer : a comprehensive review of therapeutic mechanism, clinical trials, and practical application" 2016 : 4105615-, 2016

40 Chae YK, "Challenges and future of biomarker tests in the era of precision oncology : Can we rely on immunohistochemistry(IHC)or fluorescence in situ hybridization(FISH)to select the optimal patients for matched therapy?" 8 : 100863-100898, 2017

41 Lordick F, "Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer : a phase II study of the Arbeitsgemeinschaft Internistische Onkologie(AIO)" 102 : 500-505, 2010

42 Pirker R, "Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer(FLEX) : an open-label randomised phase III trial" 373 : 1525-1531, 2009

43 Herbst RS, "Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC(SWOG S0819) : a randomised, phase 3 study" 19 : 101-114, 2018

44 Lynch TJ, "Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer : results of the randomized multicenter phase III trial BMS099" 28 : 911-917, 2010

45 Lordick F, "Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer(EXPAND) : a randomised, open-label phase 3 trial" 14 : 490-499, 2013

46 Luber B, "Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer : results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie(AIO)" 11 : 509-, 2011

47 Nielsen TO, "Assessment of Ki67 in breast cancer : updated recommendations from the international Ki67 in breast cancer working group" 113 : 808-819, 2021

48 Rudbeck L, "Adding quality to your qualitative IHC" 47 : 18-19, 2015

49 Oh DY, "A first-in-human phase I study of GC1118, a novel anti-epidermal growth factor receptor antibody, in patients with advanced solid tumors" 24 : 1037-, 2019